Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
DiscussionAlthough (mild) AEFI were demonstrated for all five studied vaccines, only a quarter of reviewed studies accounted for these, mostly in an incomplete and inaccurate manner. We provide guidance on which methods to use to better quantify the impact of AEFI on both costs and health outcomes. Policymakers should be aware that the impact of AEFI on cost-effectiveness is likely to be underestimated in the majority of economic evaluations.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Cervical Cancer Vaccine | Databases & Libraries | Genital Warts | Health Management | Human Papillomavirus (HPV) | Measles | Measles Vaccine | Medical Billing | Men | Meningitis | Meningitis Vaccine | MMR (Measles,Mumps,Rubella) Vaccine | Mumps | Mumps Vaccine | Pediatrics | Pneomococcal Vaccine | Profits and Losses | Rotavirus | Rotavirus Vaccine | Rubella | Rubella Vaccine | Study | USA Health | Vaccines